Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 1, 2007

View Archived Issues

Therapeutic agents for respiratory disorders described in recent Orchid patent

Recent patents disclose novel therapeutic agents for HCV infection

Recent patents impart new therapeutic agents for cancer

Galanin antagonist effective against depression-like behavior in rats

Snapshots of bevacizumab regimens from the Gastrointestinal Cancers Symposium

Snapshots: studies of panitumumab treatment for colorectal cancer

TLR9 agonist synergizes with cetuximab and bevacizumab against colon cancer models

FGF-19 increases energy expenditure and reduces fat mass in diet-induced obese mice

Leptin increases food intake in rats via reductions in the firing of VTA dopamine neurons

Takeda reviews Q3 developments

AlphaVax cleared to begin trials of alphavaccine candidates

Locteron begins phase IIa trial for chronic hepatitis C

PEG-Interferon lambda begins phase I study

Debiopharm signs agreement with Kirin Brewery for Debio-0719

Ipsen granted Adrovance marketing rights for France

AureoGen licenses TakaraBio's patents for aureobasidin A

LX-6171 begins phase Ib study for cognitive impairment

Exelixis files IND for XL-418

FDA awards orphan drug designation to Onconase in malignant mesothelioma

Tyrima begins clinical testing for depression and anxiety

AV-101 shows potential for neuropathic pain in preclinical studies

Kyowa Hakko and Zeria collaborate on Asacol in Japan

SPA agreement for pivotal study of Litx in metastatic colorectal cancer in the liver

SPA agreement for pivotal study of romidepsin in peripheral T-cell lymphoma

Javelin plans path to NDA filing for intranasal ketamine

Glivec approved for Ph+ ALL in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...